A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Project: Research project

Project Details

StatusActive
Effective start/end date8/30/22 → 8/29/27

Funding

  • Moderna Therapeutics, Inc: $12,500.00